Nucleic acid synthesis screening infrastructure
The global chokepoint that checks what DNA people order, and who they are, before synthetic genes are shipped or made on a benchtop device.
State of the art
Wittmann et al. (Science, October 2025) found AI-redesigned homologs of proteins of concern evaded provider screening tools, then raised detection with deployed patches; the US framework that made screening a funding condition is being revised after the May 2025 executive order, and screening is not legally mandated.
- Compliance is voluntary and uneven, so an unscreened provider is a single point of failure
- Benchtop synthesizers let users bypass commercial ordering entirely
- Generative protein design keeps producing sequences with low identity to known hazards, so signature-based screening is always catching up
- No international regime binds providers outside participating jurisdictions
Who’s working on it
Launched the Common Mechanism in May 2024, a free open-source screening package that gives any DNA provider a baseline sequence-of-concern check
- SecureDNA ↗Program
Free cryptographically private screening service that lets providers and benchtop devices check orders without exposing customer sequences
- Kevin EsveltResearcherMIT Media Lab
Drove the design of privacy-preserving universal screening and the case that benchtop synthesisers outside the voluntary system are the critical gap
- Eric HorvitzResearcherMicrosoft Research
Led the Paraphrase Project, whose October 2025 Science paper showed AI-redesigned protein sequences slipped past screening tools until patches were deployed
- International Gene Synthesis ConsortiumProgram
The industry body whose members voluntarily screen sequences and customers; it covers most commercial volume but membership is not mandatory
- Twist Bioscience ↗Company
One of the largest synthesis providers, screening all orders and customers, so its practice effectively sets the commercial floor
- Telesis BioCompany
Sells benchtop DNA synthesisers, the device class that sits outside provider-level screening and is the main reason coverage is incomplete
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| policy | Legislation mandating screening and customer verification for all providers and benchtop manufacturers, with a maintained sequences-of-concern list | $ < $10M |
| engineering | Shared, continuously red-teamed screening service with hazard-prediction models and audited benchmarking by a standards body | $$ $10M – $100M |
Depends on
A root node: no prerequisites modeled.
Required by
No other capability builds on this directly.